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Neutralizing tumour necrosis factor (TNF) antibodies have been widely used to treat inflammatory bowel dis-
ease (IBD) in the clinical practice. In this review, the principal biomarker analysis revealed that faecal calpro-
tectin, C-reactive protein, serum or mucosal concentrations of anti-TNF monoclonal antibodies (mAbs) and
antibodies to anti-TNF mAbs are commonly used as current biomarkers in the evaluation of anti-TNF thera-
peutic efficacy. However, mucosal cytokine transcripts. microRNAs, proteomics and faecal and mucosal gut
microbiota profile and mucosal histological features are reported to be novel candidates of biomarkers with
high clinical utility in the evaluation of anti-TNF therapeutic efficacy in patients with IBD. Therefore, a robust
validation of novel promising biomarkers and comparison studies between current used and novel bio-
markers are urgently required to improve their value in the evaluation of therapeutic efficacy and optimiza-
tion of personalized medicine and identification of IBD candidates for anti-TNF therapy in future clinical
practice.
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It is widely known that inflammatory bowel disease (IBD), princi-
pal types include Crohn's disease (CD) and ulcerative colitis (UC), is a
group of chronic inflammatory disorders that mainly affect the gas-
trointestinal tract. Although the aetiology for IBD remains to be fully
identified, accumulative evidence has strongly suggested that envi-
ronmental factors, genetic predisposition, and dysregulated immune
response are strongly associated with the development of IBD [13].
Clinically, the goals of IBD treatment are to induce and maintain
disease remission and mucosal healing, and then improve the
patient’s quality of life. Tumour necrosis factor (TNF)-a is a proin-
flammatory cytokine and plays an essential role in the induction and
maintenance of inflammation in the intestine [4]. As a result of this,
block of TNF signal by anti-TNF monoclonal antibodies (mAbs)
becomes a main therapeutic strategy for severe steroid refractory or
dependant IBD patients today [4]. The evaluation of therapeutic effi-
cacy in IBD patients with anti-TNF mAbs is extremely important for
optimise therapeutic strategy [5]. Clinically, there is currently no sin-
gle “gold standard” approach to assess anti-TNF therapeutic efficacyin patients with either CD or UC. Instead, it is made based on a combi-
nation of disease activity index, endoscopic observation with histo-
logical examination and biomarkers in IBD patients with anti-TNF
treatment [6]. In addition, laboratory biomarkers provide a reproduc-
ibly quantifiable tool for the evaluation of disease status and thera-
peutic efficacy in IBD patients. Therefore, the discovery of reliable
biomarkers would be extremely useful in the clinical practice and
adds a great help to assess therapeutic efficacy, minimize side-effects,
and optimize personalized medicine and strategy for identifying IBD
patients who will benefit from anti-TNF therapy [7,8].
In this study, we conducted a review that focus on current and
novel biomarkers in the context of biological therapies against TNF-
in patients with IBD.
2. A brief looking back the role of TNF-alpha in the pathogenesis
of IBD
TNF-a is a pleotropic cytokine with a potential proinflammatory
capacity and has been recognized as a triggering cytokine in the
induction of colorectal inflammation and involved in the pathogene-
sis of IBD [4] (see Fig. 1). Today, anti-TNF mAbs have been widely
introduced to treat severe steroid refractory or dependant IBD
patients in clinical practice. Clinical evidence showed that anti-TNF
therapy result in an improved clinical success including a rapid
Fig. 1. Schematic summary of TNF-a’s role and anti-TNF therapy in the pathogenesis of IBD.
Current data suggested that TNF-a plays a central role in the pathogenesis of IBD, and block of TNF-a signal by anti-TNF mAbs could significantly suppress inflammation and
improve mucosal healing.
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ity of life in ~ 60% of IBD patients. However, clinical studies reported
that 20~40% of IBD patients did not respond to anti-TNF-a induction
therapy, and ~50% of primary response IBD patients may subse-
quently loss of response to anti-TNF-a maintaining therapy after
induction period [9]. Moreover, anti-TNF-a bioagents are very expen-
sive and have several site effects. Therefore, how to evaluate thera-
peutic response and identify IBD patients who will benefit from anti-
TNF therapy becomes important [8,9].3. Current commonly used biomarkers in the evaluation of anti-
TNF therapeutic response in patients with IBD
Researchers have previously identified multiple biomarkers such
as faecal calprotectin (FC), C-reactive protein (CRP), levels of anti-
TNF-a agent level and anti-drug antibody to provide reproducible,
quantitative tools to assess disease severity and status, and therapeu-
tic efficacy in patients with IBD (see Fig. 2).
3.1. FC
Clinical results revealed that significantly reduced FC level might
predict disease remission and mucosal healing in patients with IBD
who received various therapies including anti-TNF mAbs [10]. Stud-
ies showed that the levels of FC were well correlated with endoscopic
scores of disease activity in IBD patients who received anti-TNF mAbs
[11,12]. Further studies reported that a high level of pre-treatment
baseline FC could predicate a high rate of nonresponse [13] and a
lower rate of clinical remission or mucosal healing in IBD patients
undergoing anti-TNF therapy [14,15]. Colombel et al. showed that FC
concentration is a reliable biomarker to predict treatment failure and
decision to escalate in CD patients with adalimumab treatment [16].
Increased CRP concentration could show a slightly lower predicating
significance than FC concentration. Increased concentration of FCcould significantly influence the decision to escalate after CD patients
received adalimumab treatment at different week-points [16].
3.2. Serum levels of CRP
The importance of CRP in anti-TNF induction therapy has been
intensively studied. Two clinical studies reported that a high baseline
concentration of CRP was associated with a reduced rate of clinical
remission and response to anti-TNFmAbs in steroid refractory or mod-
erate-to-severe UC patients [17,18]. Normalization of CRP levels at
week 14 could predict rates of maintained response or remission in CD
patients with IFX maintenance therapy [19]. Acute severe ulcerative
colitis (ASUC) is a clinical emergency condition that needs a prompt
therapeutic intervention [20]. Choy et al. reported that the CRP/albu-
min ratio following IFX salvage could predict the therapeutic response
and identify who at high risk of colectomy in patients with ASUC [21].
3.3. Serum levels of anti-TNF mAbs
The effective level of anti-TNF mAbs can be reflected in the level of
drugs in the blood. In a systematic review with meta-analysis, Moore
et al. [22] found that a trough threshold of IFX during maintenance
(> 2 mg/ml) was associated with a greater probability of remission
and mucosal healing in IBD patients with IFX therapy [22]. Similarly,
a high trough serum level of adalimumab could predicate a better
long-term clinical outcome in CD patients [23,24]. In contrast to
above findings, Hinojosa et al. [25] reported that low serum levels of
adalimumab were correlated with loss of clinical and endoscopic
response and low rate of mucosal healing in IBD patients with either
adalimumab induction or maintenance therapies.
3.4. Anti-drug antibody
Considerable evidence has shown that the administration of anti-
TNF mAbs into human body may induce the production of anti-drug
Fig. 2. Schematic summary of the current approaches used in the evaluation of different therapeutic efficacy in patients with IBD.
Current approaches used in the evaluation of anti-TNF therapy in patients with IBD are based on multiple clinical parameters e.g., symptom relief, changes of severity evaluated
by clinical disease activity and severity index, colonoscopy evaluation with histological examination and laboratory biomarkers.
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short and long-term response to anti-TNF mAbs in IBD patients
[26,27].
Casteele et al. [28] revealed that a cut-off anti-drug antibody value
<3.15 U/mL was correlated with disease remission in CD patients
with IFX therapy. Moreover, Brandse et al. [29] underlined that
higher serum concentrations of anti-drug antibody in IBD patients
with anti-TNF therapy may predicate a low quality of life and more
complications. In addition, Kharlamovaa et al. showed that measur-
ing drug and anti-drug antibody concentrations in IBD patients with
anti-TNF treatment could help to identify anti-drug antibody positive
IBD patients, which could lead to a more personalized and efficient
treatment regime [30]. The drug-tolerant assay method enabled to
detect anti-drug antibody earlier and regardless of drug level at time
of sampling [30]. Further studies showed that the detective rate of
anti-drug antibody in the drug-tolerant assay was much higher than
that in the drug-sensitive assay (63% vs. 21%) [31], which allows a
better follow-up of anti-drug antibody concentration changes and
observation of true transient versus persistent anti-drug antibody in
IBD patients with anti-TNF therapy.
Current biomarkers used in the evaluation of anti-TNF therapeutic
efficacy in IBD patients are summarized in Table 1 and Fig. 2.
4. Novel putative biomarkers
The specificity of current biomarkers likes CRP are relatively low;
in addition, the sensitivity of these biomarkers between patients
with CD and UC are different, which limits their clinical values in the
evaluation of anti-TNF therapeutic efficacy in patients with IBD.
Moreover, the expression levels of those biomarkers in IBD patients
with anti-TNF therapy are not always consistent with changes of dis-
ease activity and the rate of mucosal healing after treatment. There-
fore, development and identification of novel biomarkers to promote
personalised treatment of IBD patients with anti-TNF therapy is
needed. Which could better identify patients whose IBD is refractoryto the anti-TNF therapy, help clinicians to prevent unnecessary anti-
TNF-a therapy, accelerate the process of providing effective for each
patient.
4.1. Mucosal transcript landscape
4.1.1. TNF-a
Anti-TNF mAbs could significantly reduce the expression level of
TNF-a and suppress the inflammation, therefore the changed muco-
sal TNF-a transcript level might be used as a promising biomarker to
assess the anti-TNF efficacy. More recently, we have validated a cor-
relation between mucosal TNF-a transcript levels and response to
anti-TNF mAbs in UC [7]. Validation data demonstrated that baseline
mucosal TNF-a transcript level was a better biomarker with a high-
test reliability for the prediction of clinical outcomes than other clini-
cal parameters e.g., calprotectin, the UC disease activity index
(UCDAI) score, Mayo endoscopic score in patients with UC [7].
Consequently, we evaluated whether the mucosal levels of TNF-a
transcript after IFX treatment in patients with UC could predicate the
therapeutic response. We found that the mucosal TNF-a transcript
level, in responders to IFX therapy, was significantly reduced, in
which a reduced mucosal TNF-a transcript level was well correlated
to the disease remission and mucosal healing rate examined by colo-
noscopy observation in both UC and CD responders with anti-TNF
introduction therapy [3234]. Furthermore, normalization of muco-
sal TNF-a transcript levels could predicate a good long-term disease
remission in UC responders with discontinuing anti-TNF therapy
[35].
4.1.2. IL-17A
TH17 signature cytokine IL-17A has been repeatedly shown to be
a valuable candidate biomarker to assess anti-TNF efficacy in patients
with IBD. Our data showed that UC patients with a higher mucosal IL-
17A transcript level tended to have a higher rate of disease remission
in response to three IFX infusions, showing a predicate value in UC
Table 1
Significance of commonly used current biomarkers in the evaluation of anti-TNF therapeutic efficacy in patients with IBD in the clinical
practice.
Biomarker Decreased or normalized in CD Decreased or normalized in UC
Response Remission Mucosal healing Response Remission Mucosal healing
Faecal calprotectin + [13] + [79] + [11] + [79] + [79] + [12]
CRP + [75, 80] + [81] + [82] + [83] + [19] + [82]
Serum levels of anti-TNF drugs + [22, 25, 84, 85] + [22-24, 28] + [22, 25] + [86] + [86] + [87]
Anti-drug antibody + [88, 89] + [28, 90] + [89] + [88] + [91] + [89]
(reference ID].
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mucosal IL-17A transcript level was associated with complete muco-
sal healing defined by colonoscopy examination in CD patients
received adalimumab treatment [33], and normalized mucosal IL-
17A transcript level after IFX therapy appeared to predicate a long-
term disease remission in patients with CD [34].
4.1.3. IL-7 receptor (IL-7R)
Belarif et al. [37] reported that increased mucosal IL-7R transcript
levels were associated with non-responders of severe CD and UC
patients to either immunosuppressive/corticosteroid, anti-TNF, or
anti-a4b7 therapies. High expression of both IL7R and IL-7R signal-
ling signature in the colon before treatment was closely associated
with nonresponse rate to anti-TNF therapy in patients with IBD. Their
findings suggest that an overexpression of mucosal IL-7R correlated
strongly to failure of anti-TNF therapy in patients with CD and UC. Its
value as a biomarker candidate remains to be validated.
4.1.4. Cytokine oncostatin M (OSM) and its receptor (OSMR)
Cytokine OSM belongs to IL-6 subfamily and can be produced
by several types of immune and stromal cells. More recently, Kim
et al. [38] reported that high mucosal levels of both OSM and its
receptor OSMR were strongly associated with the inflammation
degree and disease severity in patients with IBD. Furthermore,
anti-TNF-resistant IBD mice lacking OSM developed less inflam-
mation and colitis than wild-type mice [38]. Genetic deletion or
pharmacological blockade of OSM could significantly attenuate
the process of colitis. In patients with IBD, a high expression level
of OSM was associated with the failure of anti-TNF (IFX and goli-
mumab) therapies [38]. Therefore, OSM might be considered as a
biomarker candidate in the evaluation of anti-TNF therapeutic
efficacy in patients with IBD [39].
4.1.5. Other cytokines
Our data demonstrated that in addition to decreased TNF mRNA
level, IFX therapy in patients with UC also induced a decreased
mRNA levels of interferon (IFN)-g in inflamed mucosa [32]. Mavra-
gani et al. [40] have reported that levels of type I and II IFN genes in
the serum could predict the response to IFX in patients with IBD. Res-
ponders tended to have significant decreased level of both types of
interferon [40]. Their studies confirmed that both Types I and II IFN
gene can be the candidates of biomarker for IFX therapy.
4.2. Triggering receptor expressed on myeloid cells 1 (TREM1)
Studies showed that TREM-1 was involved in the development of
inflammation and anti-TNFa responsiveness mechanism, and levels
of TREM-1 in peripheral blood and inflamed mucosa were a potential
biomarker of anti-TNF therapeutic efficacy in patients with IBD
[41,42]. Gaujoux et al. [42] reported baseline serum TREM-1
(sTREM1) concentration may predicate anti-TNF response with very
high accuracy in patients with CD, responders had a higher level of
TREM-1 than non-responders. In inflamed mucosa, TREM1 expres-
sion level was also decreased in IFX responders [42]. However,Verstockt et al. observed a opposite connection between sTREM-1
level and mucosal healing. CD patients with anti-TNF therapy (adali-
mumab and infliximab) who achieved mucosal healing after 6
months tended to have a lower baseline sTREM-1 levels than those
non-responders [41]. Recently, they further showed that low sTREM1
level could predict anti-TNF response in both CD and UC [43]. Such
discrepancy between two results might potentially be attributed to
differences in several aspects e.g., sample size, definition standards of
response and different ethnicity [41]. Thus, whether the expression
level of sTREM-1 could be an accurate biomarker for the evaluation
of anti-TNF response remains to be validated in well-designed studies
with large sample size.
4.3. Faecal and mucosal microbiota profile
Faecal microbiota was a rich source of biomarkers that were asso-
ciated with intestinal inflammation [44]. Magnusson et al. [45]
reported that the gut microbiota profile between responders and
non-responders was different. Responders tended to have a lower
dysbiosis indexes and a higher abundance of Faecalibacterium praus-
nitzii than non-responders at baseline. In addition, an increased
abundance of Faecalibacterium prausnitzii was observed in respond-
ers during the IFX/adalimumab induction therapy [45]. Therefore,
this finding might discriminate responders from non-responders at
baseline. The metabolomic analyses of faecal samples showed that
metabolite exchange was significantly associated with later clinical
remission in patients with IBD who received anti-TNF therapy [44].
Vatn and European colleagues [46] reported that differences were
observed for some bacterial markers, but they did not find a statisti-
cal significance between responders and non-responders in IBD
patients with anti-TNF therapy. Dovrolis et al. [47] found that the
populations of several bacterial genera in IBD patients were dramati-
cally decreased after IFX therapy regardless of response. Their study
further revealed that IFX treatment could significantly impact the gut
microbial composition and the inflamed tissue transcriptome in IBD
patients. In which, enterotypes at baseline correlates with transcrip-
tome changes and could differentiate IFX responders versus non-res-
ponders and predicts anti-TNF response in patients with IBD [47].
Other studies confirmed that altered gut microbiota profile could
reflect the rate of biotherapy response in patients with CD [48]. More
recently, Wang et al. [49] examine the changed faecal microbiota pro-
file in paediatric CD patients with anti-TNF therapy. They found that
IFX in paediatric CDs could increase the bile salt hydrolases-produc-
ing bacteria, higher abundances of Methylobacterium, Sphingomo-
nas, Staphylococcus, and Streptococcus were associated with a
higher rate of sustained response in these patients with IFX therapy
[49]. In a systematic review with 8 anti-TNF studies in patients with
IBD, Estevinho et al. [50] indicated that the microbiomes of faecal or
colon samples taken from IBD patients, in response to anti-TNF thera-
pies, showed a decreased abundance of Escherichia and Enterococcus
bacteria, but increased abundance of short-chain fatty acid-producing
bacteria. In addition, higher microbial diversity at baseline or
throughout treatment was associated with response to anti-TNF ther-
apy [50].
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MicroRNAs (miRNAs) are small, non-coding RNAs and are involved
in the proinflammatory cytokine production and inflammation process
as seen in IBD. Thus, circulating and faecal miRNAs have been consid-
ered as novel biomarker candidates that predict therapeutic response
in patients with IBD [51]. For example, Batra et al. validated that the
expression of seven miRNAs showed in remarkable changes after treat-
ment in responders but not in non-responders in a small cohort of pae-
diatric IBD with diverse treatments including anti-TNF mAbs [52].
However, a Greek group evaluated the association of miRNA polymor-
phismswith anti-TNF treatment response [53] did not detect any corre-
lations between studied miRNA (miR-146 rs2910164, miR-196a
rs11614913, miR-221 rs113054794 and miR-224 rs188519172) poly-
morphisms and patients’ response to anti-TNF mAbs in 107 CDs. There-
fore, the profile of serum or mucosa miRNAs as promise biomarkers in
analysing the therapeutic response to anti-TNF mAbs in IBD patients
remains to be investigated in future clinical practice.
4.5. Proteomics
The interaction between environmental factors and susceptible
genes will inevitably result in a significant alteration of proteome pro-
file in both serum and inflamed mucosa of IBD, which has been
recently considered as the potential diagnostic and differentiate bio-
markers for IBD [54]. For instance, Meuwis et al. reported that 4 serum
proteins (platelet aggregation factor 4, haptoglobin a2, fibrinopeptide
A, and myeloid-related protein 8) were associated with acute-phase
inflammation and tended to be high sensitivity and specificity diag-
nostic biomarkers in patients with IBD [55]. Zhang et al. [56] reported
that serum proteomic profiling may have a diagnostic value in differ-
entiating IBD from intestinal tuberculosis. Starr et al. [57] showed that
a panel of five proteins as candidate biomarkers that could distinguish
patients with paediatric IBD from controls, and a panel of 12 proteins
that enable differentiation between CD and UC [57]. Furthermore, Dro-
bin et al. [58] have identified that 13 serum proteins were associated
with cytokine signalling, immune-metabolic regulation, and immune
cell activation in IBD patients.
Changed inflammation-related proteomic profiling could also be
biomarker candidates in the evaluation of therapeutic response in IBD.
Medina-Medina et al. [59] identified that 17 proteins regulated by acet-
ylation had a predicting value for primary response to anti-TNF therapy
and 4 proteins were potential biomarkers of loss of response in 54 CD
patients. D'Haens et al. [60] recently developed a validation test to
identify remission in CD patients with biologicals, based on serum lev-
els of 13 proteins (ANG1, ANG2, CRP, SAA1, IL-7, EMMPRIN, MMP1,
MMP2, MMP3, MMP9, TGFA, CEACAM1, and VCAM1) combined with
the endoscopic healing index analysis. Their validation results showed
that this test could accurately identify remission in CD patients, which
were comparable to measurement of FC and higher than measurement
of serum CRP [60]. Pierre et al. [61] identified that protein biomarker
candidates could be distinctly classified as biomarkers associated with
the risk of short-term and biomarkers associated with mid/long-term
relapse in CD patients with IFX biological treatment, which related to
different pathophysiological processes. Their results might help the
clinicians to select the protein biomarker candidates for the evaluation
of short-term and mid/long-term relapse in response to anti-TNF
mAbs. However, Telesco et al. [62] reported that the specificity of a
panel of 13 candidate biomarkers at gene levels in predicating mucosal
healing response to golimumab treatment in patients with UC was low
and not sufficient for the clinical utility.
4.6. Genomic
Susceptibility loci in IBD can be identified [63], the value of differ-
ent genomic biomarkers such as functional polymorphisms in therelevant genes encoding in predicating response to TNF therapy in
patients with IBD has been evaluated [64,65]. Since the target of anti-
TNF mAbs is on TNF, the functional polymorphisms for TNF and TNF
receptor superfamily have attracted much attention and researched
[63,64]. Studies revealed that polymorphisms in cytokine pathways
(IL-1B, IL-6, IFN-gamma, TNFRSF1A, NLRP3, IL1RN, IL-18, and JAK2),
the NFkB pathway (TLR2, TLR4 and NFKBIA) were closely associated
with response to anti-TNF therapy in patients with IBD [64,66]. Poly-
morphisms in encoding many other genes such as HLA-DQA1*05
have also been reported to be associated with response to anti-TNF
therapy [67].
Recently, the development of genomic-relevant serological anti-
bodies in patients with IBD has been reported. Degenhardti et al. [68]
showed that the tested serological antibodies anti-GP2 IgA and IgG
were associated with CD and had a high discriminatory capability for
CD versus UC. In addition, a genome wide association study of anti-
body expression in their cohort could identify distinct loci associated
with levels of anti-GP2 isoform beta IgG and IgA, many of which are
known susceptibility loci for IBD [68]. However, their significance in
the evaluation of anti-TNF efficacy in CD verse UC has not been stud-
ied. Finally, biomarkers might also play a key role in differentiating
paediatric- from adult-onset IBD. For example, genome-wide associa-
tion study (GWAS) has revealed the single-nucleotide polymorphism
differences in the polygenic architecture between paediatric- and
adult-onset IBD [69]. Which could be the potential genetic bio-
markers to study the role and significance of accumulated rare and
deleterious variants in affected paediatric- and adult-onset.
4.7. Other new biomarkers
The therapeutic response to anti-TNF mAbs may also induce
changes of mucosal histology. We found that densities of T lympho-
cytes and macrophages were significantly decreased in UC patients
with healed mucosa after IFX introduction treatment [32]. Li et al.
[70] reported that both UC and CD patients with IFX therapy showed
a sustained decreased population of regulatory T cells (Tregs) in
peripheral blood and downregulated expression level of FoxP3 (a
marker for Tregs) transcript in inflamed mucosa, particularly in UC
and CD responders. However, as many immune cell and new subsets
of lymphocytes such as TH9 and TH22 have been identified in the
colorectal mucosa [71], their exact role in the pathogenesis of IBD
and therapeutics remains unclear.
More recently, Osterman et al. [72] reported that ileal microvillar
length has a significance to predict the therapeutic response to uste-
kinumab (mAbs to IL-12 and IL-23) and Vedolizumab (mAbs to integ-
rin) in patients with CD. However, the predicative value of ileal
microvillar length in IBD patients with anti-TNF mAbs remains to be
investigated. Andreou et al. [73] showed that serum B-cell activating
factor (BAF) concentration at baseline in CD response to IFX was
higher than CD non-response to IFX. Which was associated with its
polymorphisms. Importantly, serum BAF concentration in CD res-
ponders was remarkably reduced after IFX [73]. Their findings sug-
gest that serum BAF might have a predicating significance for anti-
TNF therapy. Reports indicated that low serum albumin levels could
predicate a worse response to IFX or golimumab in patients with UC
[18,74].
For the convenience for readers, we have summarized selected
novel biomarkers in Table 2.
5. Combination, validation and comparison studies between
current and novel biomarker in the evaluation of anti-TNF
therapeutic response in IBD
The use and significance of different biomarkers in the clinical
practice might be varied. Some biomarkers such as genomic, RNA
and protein levels, and FC concentration have been frequently used
Table 2
Novel putative biomarkers in the evaluation of anti-TNF therapeutic efficacy in patients with IBD.
Biomarker Decreased or normalized in CD Decreased or normalized in UC
Response Remission Mucosal healing Response Remission Mucosal healing
Mucosal transcripts
TNF-a + [33, 34] + [33, 34] + [33, 34] + [35] + [35] + [35]
IL-17A + [34] + [34] + [34] + [33, 36] + [33, 36] + [33, 36]
OSM + [38, 39] + [38, 39] + [38, 39] + [38, 39]
IL-7R + [37] + [37]
TREM1 + [41, 43] + [41, 43]
miRNAs + [52, 53] + [52]
Faecal and mucosal microbiota profile + [44, 46, 48, 49] + [4446]
Proteomics + [59, 76]
Genomic + [63, 64] + [63, 64]
TNF-a: tumour necrosis factor-a; IL-17A: interleukin-17A; miRNAS: MicroRNAs; OSM: Oncostatin M; IL-7R: interleukin-7 receptor; TREM1: Trig-
gering receptor expressed on myeloid cells 1.
(reference ID).
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with CD [16,65]. However, the level of drugs and ADA are often
applied to the monitoring of anti-TNF therapy. Mucosal TNF tran-
script is a biomarker that not only help in evaluation of therapeutic
response, but also help to identify the candidates who should prior to
the administration and personation of anti-TNF mAbs in patients
with UC [7]. Moreover, the accuracy and power of individual bio-
marker in the evaluation of therapeutic response in patients with IBD
might be low. One of strategies to improve the power of biomarkers
in clinic is to use the combination of different biomarkers in the eval-
uation of anti-TNF therapeutic response in patients with IBD [6].
Roblin et al. [75] reported that CRP levels, together with IFX trough
levels and anti-drug antibody levels were associated with the rate of
loss response to infliximab in patients with IBD. However, how to
optimally group these different biomarkers for clinical use is a partic-
ular future task.
Vatn et al. [46] have compared faecal microbiota profile with
other inflammatory biomarkers such as CRP and faecal calprotectin
in patients with IBD, they observed a strong correlation between the
degree of dysbiosis and the faecal calprotectin levels. Alterations inFig. 3. Schematic summary of the statues of current and novel laboratory biomarkers used in
Many laboratory factors have been used as biomarkers in the evaluation of anti-TNF th
been well validated in clinical studies with a larger sample size. Future comparison studie
markers in clinic in the evaluation of anti-TNF therapeutic response in patients with IBD are wmicrobiota composition have previously been associated with
response to anti-TNF therapy [45]. However, they could not validate
such correlation between changed microbiota and anti-TNF thera-
peutic response [46]. More recently, our group have validated the
value of mucosal TNF transcript as a reliable biomarker in the evalua-
tion of anti-TNF therapeutic response in patients with UC [7]. We
were able to show that baseline mucosal TNF-a transcript level was a
better biomarker than other clinical parameters e.g., calprotectin, the
UC disease activity index (UCDAI) score, Mayo endoscopic score in
patients with UC [7]. Meuwis et al. [76] validated that changed serum
proteins could predict the therapeutic response to anti-TNF in a small
cohort of CD patients. Haberman et al. validated that a subset of
severity genes and changed microbiota profile are associated with
response to anti-TNF mAbs in adult UCs [77]. However, the sensitivity
and specificity of most of them require validation studies on a larger
cohort of patients (see Summarized in Fig. 3). Therefore, validation of
current and novel biomarkers in well-designed studies with large
patient size should be considered in the future. In addition, whether
one biomarker is better than another biomarker in reflecting disease
activity change is important for its use in the evaluation ofthe evaluation of anti-TNF therapy in patients with IBD
erapeutic response. However, the sensitivity and specificity of most of them have not
s between current and novel biomarkers and the combination power of different bio-
aiting to be conducted.
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edge, high-quality comparison studies between commonly used cur-
rent and novel biomarkers are waiting to be conducted. These works
are extremely important for the selection and development of ideal
biomarkers, optimization of personal medicine and strategy for iden-
tifying IBD patients who will benefit from anti-TNF therapy in the
future clinical practice.
6. Limitations of this review
Due to the high number of biomarkers and publications in bio-
marker research field, we focused this review only on commonly
used and selected novel biomarkers for the evaluation of anti-TNF
therapeutic efficacy in patients with IBD. We could have missed
some promising novel biomarkers. Future reviews could be extended
to include these biomarkers in the evaluation of anti-TNF efficacy
when the data is sufficient. Furthermore, the accuracy and potential
value for these novel biomarkers in the evaluation of response to
anti-TNF therapy in IBD patients need to be validated in large sample
size cohorts of IBD patients. Finally, because of sample size, anti-TNF
mAbs and methodological heterogeneity of included studies, we did
not conduct a formal assessment of quality and risk of bias of
included studies and a meta-analysis for individual biomarkers was
not carried out in this review.
7. Conclusions
Anti-TNF strategy has been widely used and shows a significant
benefit in the management of severe steroid refractory or dependant
IBD patients. How to find reliable laboratory biomarkers may signifi-
cantly help the evaluation, improvement and personalization of anti-
TNF therapy in the clinical practice. Most biomarkers seem to reflect
a generalized inflammation, are not IBD specific. Therefore, their
usage and clinical significance in IBD patients with different types of
anti-TNF mAbs are non-different.
Many new biomarkers are reported. However, most of them
reflect a generalized inflammation, are not CD or UC specific. There-
fore, the inflammatory biomarkers usually cannot differentiate CD
and UC. One of the main works in the future is to validate these novel
biomarkers in well-designed studies with large size of IBD patients.
Furthermore, comparison studies between current and novel bio-
markers are necessary, which may help the clinicians to select reli-
able biomarkers, better evaluate efficacy and personalize medicine of
anti-TNF therapy in the future clinical practice.
8. Outstanding questions
The importance of biomarkers in the evaluation of therapeutic
efficacy in patients with IBD has been intensively studied. Current
analysis provides new insights and challenges to optimize personal
anti-TNF strategy (precision medicine) in patients with IBD.
8.1. Optimize the use of different biomarker for clinical practice
Can we classify the laboratory biomarkers into categories such as
surveillance of disease activity, monitoring therapeutic response and
predicating prognosis [78]?
8.2. Biomarkers in the candidate selection prior to for the
administration of anti-TNF mAbs
Some biomarkers such as mucosal TNF transcript could predicate
the response rate to anti-TNF mAbs [34]. Should we measure the lev-
els of the biomarker before we decide to prescribe anti-TNF mAbs to
a patient? Should those patients with a high level of the biomarker
be in the priority of consideration for anti-TNF therapy?8.3. Optimizing dose and duration of anti-TNF mAbs
The levels of some biomarkers such as FC and serum CRP could
predicate the failure rate in IBD patients with anti-TNF therapy [16].
How to identify a correlation between the dose/duration of anti-TNF
mAbs and the biomarker levels?
To improve the accuracy and power of individual biomarker in the
clinic, one of strategies is to combinate different biomarkers in the
evaluation of anti-TNF therapeutic response in patients with IBD.
However, how to optimally group different biomarkers for clinical
use remains to be investigated.
8.4. Search strategy and selection criteria
A literature research was electronically carried out in academic
databases PubMed, MEDLINE and Google scholar by the authors using
the search terms “biomarker”, “inflammatory bowel diseases”, “ulcer-
ative colitis”, “Crohn’s disease”, “anti-TNF treatment”, “efficacy”,
“predicators”, “C-reactive protein”, “calprotectin”, "infliximab level",
"anti-infliximab”, "adalimumab level" and "anti-adalimumab". After
screening the abstracts, relevant publications from appropriate
papers added as additional literature sources.
We used the following eligibility criteria to include publications in
this systematic review (2): (1) article written in English and full-text
available; (2) only studies performed in humans; (3) individual
patient information; (4) studies only published as abstract or not in
English were excluded.
The electronic literature search resulted in a total of 2651
abstracts (2641 in English from MEDLINE, PUBMED and Google
scholar, 10 full-text publications in English by cross-reference
search), latest search date: 31st of May 2020. Of which 91 full-text
publications were finally included for analysis after excluding publi-
cations not meeting the selection criteria.
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